Lu Peihua, Tsang Tom, Badowski Michael S, Pennington Michael E, Meade-Tollin Linda C
Department of Hematology and Oncology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, China.
School of Medicine, Jiangnan University, Wuxi, China.
Cancer Med. 2024 Dec;13(23):e70469. doi: 10.1002/cam4.70469.
Rising cancer care costs are becoming cost prohibitive for lower income people worldwide. We developed the Warburg protocol as a low-cost option for the treatment of cancer that was inspired. It was developed to exploit an Achilles heel which is a hallmark of cancer cells; the metabolic requirement for higher levels of glucose than normal cells.
The purpose of this report is to assess the clinical safety and affordability of the Warburg therapy as an option for patients with advanced cancers.
Between 2021 and 2023, 251 patients with advanced cancers received a total of 8542 treatments with the Warburg therapy. To restrict the supply of blood glucose to cancerous tumors, regular human insulin was administered (IV) sufficient to reduce blood glucose concentrations to hypoglycemic levels for 40-60 min. Subroutine doses of fluorouracil and cyclophosphamide were administered intravenously during this hypoglycemic period. Food or intravenous glucose was given as needed to return blood glucose to euglycemic levels after treatment. Patient symptoms, status, vitals, blood glucose, and hypoglycemic symptoms were monitored throughout treatment. Various blood parameters were measured before and after patients' course of treatment.
There were no irreversible adverse reactions in advanced tumor patients of different ages and different cancer types after treatment. There was no significant fluctuation in blood glucose levels in diabetic and non-diabetic patients after treatment, and the weight, vital index and blood biochemical index of patients before and after multiple treatments exhibited little variation.
Warburg therapy for the treatment of advanced tumors is clinically feasible, and safe for multiple treatments. It is inexpensive and widely applicable to different patient groups.
不断上涨的癌症治疗费用对全球低收入人群来说正变得难以承受。我们开发了瓦尔堡方案，作为一种低成本的癌症治疗选择，其灵感来源于癌细胞的一个致命弱点，即癌细胞对葡萄糖的代谢需求高于正常细胞。
本报告的目的是评估瓦尔堡疗法作为晚期癌症患者治疗选择的临床安全性和可承受性。
在2021年至2023年期间，251例晚期癌症患者接受了总共8542次瓦尔堡疗法治疗。为了限制癌性肿瘤的血糖供应，静脉注射常规人胰岛素，使血糖浓度降低至低血糖水平40 - 60分钟。在此低血糖期间，静脉注射亚常规剂量的氟尿嘧啶和环磷酰胺。治疗后根据需要给予食物或静脉注射葡萄糖，使血糖恢复至正常血糖水平。在整个治疗过程中监测患者的症状、状态、生命体征、血糖和低血糖症状。在患者治疗前后测量各种血液参数。
不同年龄和不同癌症类型的晚期肿瘤患者治疗后均未出现不可逆的不良反应。糖尿病患者和非糖尿病患者治疗后血糖水平无明显波动，多次治疗前后患者的体重、生命体征指标和血液生化指标变化不大。
瓦尔堡疗法治疗晚期肿瘤在临床上是可行的，多次治疗安全，费用低廉，广泛适用于不同患者群体。
